Giacomo Iovane^1,*, Luca Traman², Michele Maffezzoli^1,3, Giuseppe Fornarini², Domenico Corradi⁴, Debora Guareschi⁴, Matteo Santoni^5,#, Sebastiano Buti^1,#

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523 - 30 December 2025

Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:… More > Graphic Abstract

Erin Howells¹, Lucas Wigston², Gavin Mackie¹, Ben Tran³, Louise Nott⁴

Canadian Journal of Urology, Vol.30, No.3, pp. 11558-11561, 2023

Abstract Fumarate hydratase deficient (FHdef) renal cell carcinoma (RCC) is rare, highly aggressive and is believed to arise mostly in the setting of hereditary leiomyomatosis RCC (HLRCC) syndrome with a germline mutation of fumarate hydratase (FH) gene. There is currently little evidence regarding the most effective systemic treatment for advanced FHdef RCC. We present three cases of metastatic FHdef RCC, all achieving tumor response with combination immunotherapy ipilimumab and nivolumab (Ipi/Nivo). A 50-year-old male, a 27-year-old male and a 48-year-old female. The clinical features, diagnosis and medical imaging are reviewed. More >

Doreen A. Ezeife¹, Brendon Josh Morganstein², Steven Yip¹, Malcolm Ryan², Jennifer H. Law², Amy Yimin Guan³, Lisa W. Le³, Aaron R. Hansen², Adrian Sacher², Georg A. Bjarnason⁴, Mark K. Doherty⁴, Natasha B. Leighl²

Canadian Journal of Urology, Vol.28, No.4, pp. 10762-10767, 2021

Abstract Introduction: Advances in novel treatment options may render renal cell cancer (RCC) patients susceptible to the financial toxicity (FT) of cancer treatment, and the factors associated with FT are unknown.
Materials and methods: Eligible patients were ≥ 18 years old and had a diagnosis of stage IV RCC for at least 3 months. Patients were recruited from Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre (Toronto, Canada). FT was assessed using the validated Comprehensive Score for Financial Toxicity (COST) instrument, a 12-question survey scored from 0-44, with lower scores reflecting worse FT. Patient and treatment characteristics,… More >

BENJIANG QIAN¹, YOUFENG HUANG², ZHENQIANG QIU², XIAOYAN YING³, GUANG YANG³, HUIZHANG LI^2,*, JIANMING TAN^1,*

BIOCELL, Vol.45, No.3, pp. 599-615, 2021, DOI:10.32604/biocell.2021.014633 - 03 March 2021

Abstract Tet methylcytosine dioxygenase 2 (TET2) acts as an antioncogene that is investigated in different cancers. But the effects of TET2 in renal cell cancer (RCC) is still known little. Here, quantitative real-time PCR (qRT-PCR), Western blot, and immunofluorescence were performed to exam gene and protein expression. Cell proliferation was measured using Cell Counting Kit-8 (CCK-8). Transwell assay was performed to detect cell metastasis viability. Flow cytometry was performed to analyze the cell cycle and cell apoptosis. The effects of TET2 on RCC growth in vivo was analyzed using a mouse xenograft model.We found that TET2 More >

FANGHAO SUN¹, WENCHAO ZHAO¹, LIANSHENG ZHANG², HONGGUI MA¹, JIAN ZHOU¹, YOUGAN CHEN¹, JIANQUAN HOU^1,*

BIOCELL, Vol.44, No.4, pp. 639-647, 2020, DOI:10.32604/biocell.2020.013053 - 24 December 2020

Abstract Recent studies suggested that LIM and SH3 protein 1 (LASP-1) is a promising therapeutic target for renal cell cancer (RCC). This study aimed to explore the role of LASP-1 in RCC. For this purpose, LASP-1 expression in RCC tissues was analyzed by immunohistochemistry and Western blot analysis. Cell proliferation, migration, invasion, and gene expression were detected by CCK-8 assay, Transwell assay, and Western blot analysis. The results showed that LASP-1 was highly expressed in RCC, and its expression level,t was positively correlated with lymph node metastasis and tumor, nodes, and metastases (TNM) stage. The knockdown More >

Makoto Isono, Akinori Sato, Kazuki Okubo, Takako Asano, Tomohiko Asano

Oncology Research, Vol.24, No.5, pp. 327-335, 2016, DOI:10.3727/096504016X14666990347635

Abstract The histone deacetylase (HDAC) inhibitor belinostat increases the amount of unfolded proteins in cells by promoting the acetylation of heat shock protein 90 (HSP90), thereby disrupting its chaperone function. The human immunodeficiency virus protease inhibitor ritonavir, on the other hand, not only increases unfolded proteins by suppressing HSP90 but also acts as a proteasome inhibitor. We thought that belinostat and ritonavir together would induce endoplasmic reticulum (ER) stress and kill renal cancer cells effectively. The combination of belinostat and ritonavir induced drastic apoptosis and inhibited the growth of renal cancer cells synergistically. Mechanistically, the combination More >

Shi-Ming Tu, Adrienne H. Chen

Canadian Journal of Urology, Vol.19, No.3, pp. 6268-6268, 2012

Abstract This article has no abstract. More >

Petar Erdeljan¹, Mrinal Dhar², Geoff Wignall³, Roman Kozak⁴, Stephen E. Pautler^1,5

Canadian Journal of Urology, Vol.18, No.5, pp. 5903-5907, 2011

Abstract Introduction: Cryoablation (CA) and radiofrequency ablation (RFA) are nephron-sparing procedures that destroy renal tissue in situ rather than by surgical removal. Both thermal ablative techniques are recommended for select patients with small renal masses and multiple comorbidities that may preclude major surgery. Unfortunately, the long-term oncologic outcomes of these procedures remain unknown.
Materials and methods: We report oncologic outcomes following CA and RFA in patients with small renal masses from a single institution over a 48-month follow-up period. A total of 30 patients underwent thermal ablation for a small renal mass: 7 received RFA and 23 underwent CA.
… More >

Attila Szendröi¹, Miklós Szendröi², Miklós Szücs¹, Eszter Székely³, Imre Romics¹

Canadian Journal of Urology, Vol.17, No.6, pp. 5475-5477, 2010

Abstract Case report: A renal cell cancer patient with late onset of multiorgan metastases showed an unusually long survival following surgical resection. Femoral metastasis appeared 11 years, and contralateral kidney and adrenal gland metastasis 19 years after the primary nephrectomy, respectively. Following the resection of the femur and implantation of endoprosthesis and removal of adrenal gland and partial nephrectomy, the patient was disease-free 20 years after the first diagnosis of cancer.
Conclusion: The long survival and successful treatment underline the importance and efficiency of radical metastasectomy even in the case of late onset multiorgan metastases of renal cell More >

Daniel Taussky¹, Denis Soulières²

Canadian Journal of Urology, Vol.16, No.2, pp. 4599-4600, 2009

Abstract We present a case of a patient with metastatic renal cell cancer (RCC) treated with hypofractionated radiotherapy while being treated with sunitinib. He received a single dose of 8 Gy of external beam radiation to a metastatic mass of several centimeters diameter in the right lateral ribs, followed by a second identical dose. Clinically, the patient achieved a nearly complete disappearance of the mass. We discuss the possible synergy between tyrosine kinase receptor inhibitors (TKRIs) and radiotherapy and the importance of dose fractionation. More >